Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19

Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Zumbrun, Elizabeth E., Kaku, Chengzi I., Dillinger, Lukas, Zak, Samantha E., Kuehne, Ana I., Bakken, Russel R., Koehler, Jeffrey W., Delp, Korey L., Stefan, Christopher P., Kumar, Raina, Kugelman, Jeffrey R., Moreau, Alicia M., Zeng, Xiankun, Dye, John M., Herbert, Andrew S., Narayan, Kristin, Walker, Laura M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872613/
https://www.ncbi.nlm.nih.gov/pubmed/36519929
http://dx.doi.org/10.1128/aac.01353-22
Descripción
Sumario:Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.

Ejemplares similares